| Editor’s Note: Fierce Biotech will not publish on Monday, May 27, in observance of the Memorial Day holiday. We'll be back in your inbox on Tuesday, May 28. Enjoy your long weekend! |
|
Among the most promising immunotherapy approaches are immune checkpoint blockade, adoptive cell therapies, therapeutic vaccines, oncolytic viruses, and mono, bi and trispecific antibodies. Download our white paper to explore advances in cancer immunotherapy and learn how Premier Research can maximize the potential of your program throughout the development lifecycle. +114x60.png)
|
|
Today’s Big NewsMay 24, 2024 |
| By Annalee Armstrong Johnson & Johnson’s radiopharmaceutical spurred “profound and durable” responses, however, four patient deaths in the early-stage trial marred the results. |
|
|
|
By James Waldron Analysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’ expectations for the bispecific antibody. |
By Gabrielle Masson With analysts looking for a meaningful increase in the number of responses for Regeneron's phase 1/2 solid tumor trial, a fresh data slice shows just one complete response across 94 patients. |
By Gabrielle Masson,Andrea Park Almost exactly five months after CRISPR Therapeutics’ former chief medical officer P.K. Morrow announced her impending departure, the gene editing company has found a replacement in Naimish Patel, M.D. |
|
One major hurdle in therapeutic development is the risk for unwanted immunogenicity, which can lead to decreased efficacy and safety. Gain insight into available tools and de-risk your pipeline - Join your colleagues to discuss on May 22 
|
|
By James Waldron Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist may have only managed at best an average 4.3% reduction in weight when given in low doses, but the Danish company is keen to stress that higher doses are where the drug should prove its worth. |
By Helen Floersh A novel, non-hormonal reversible contraceptive for men appears to be effective in mice, the results of a study sponsored by Promega show. When the mice were taken off the drug, their fertility returned. |
By Fraiser Kansteiner Early Friday, Novo shared full, positive results from the FLOW trial assessing the ability of once-weekly semaglutide 1.0 mg to help combat major kidney outcomes such as kidney failure, loss of kidney function and death from kidney or cardiovascular causes in people with Type 2 diabetes and chronic kidney disease. |
By Conor Hale Guardant Health’s Shield blood test, designed to help screen the population for hidden cases of colorectal cancer, may have taken a step closer to FDA approval. |
By Ayla Ellison,Fraiser Kansteiner This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing. |
By Angus Liu AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour BioMed, and it plans to build a $1.5 billion ADC plant in Singapore. Hengrui and Elevar's proposed PD-1/VEGFR liver cancer combination has been rejected by the FDA. Plus more. |
Fierce podcasts Don’t miss an episode |
| This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
Whitepaper This detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
